Effect of CYP2D6 variants on venlafaxine metabolism in vitro

References

• Bertilsson L, Dahl ML, Dalen P, et al. (2002). Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53:111–22
   PubMed Web of Science ®Google Scholar
• Bolden-Watson C, Richelson E. (1993). Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 52:1023–9
   PubMed Web of Science ®Google Scholar
• Dai DP, Geng PW, Wang SH, et al. (2015). In vitro functional assessment of 22 newly identified CYP2D6 allelic variants in the Chinese population. Basic Clin Pharmacol Toxicol 117:39–43
   PubMed Web of Science ®Google Scholar
• Dai DP, Wang YH, Wang SH, et al. (2013). In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population. Acta Pharmacol Sin 34:1449–56
   PubMed Web of Science ®Google Scholar
• Etienne L, Yessine M-A, Hamelin BA, et al. (1999). Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 9:435–43
   PubMedGoogle Scholar
• Fukuda T, Nishida Y, Imaoka S, et al. (2000). The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch Biochem Biophys 380:303–8
   PubMed Web of Science ®Google Scholar
• Fukuda T, Yamamoto I, Nishida Y, et al. (1999). Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol 47:450–3
   PubMed Web of Science ®Google Scholar
• Hicks JK, Swen JJ, Gaedigk A. (2014). Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. Curr Drug Metab 15:218–32
   PubMed Web of Science ®Google Scholar
• Hiratsuka M. (2012). In vitro assessment of the allelic variants of cytochrome P450. Drug Metab Pharmacokinet 27:68–84
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6–13
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Sim SC, Gomez A, et al. (2007). Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526
   PubMed Web of Science ®Google Scholar
• Kong LM, Qian MR, Hu HH, et al. (2012). Comparison of catalytical activity and stereoselectivity between the recombinant human cytochrome P450 2D6.1 and 2D6.10. Die Pharmazie 67:440–7
   PubMed Web of Science ®Google Scholar
• LLerena A, Naranjo ME, Rodrigues-Soares F, et al. (2014). Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin Drug Metab Toxicol 10:1569–83
   PubMed Web of Science ®Google Scholar
• Marcucci KA, Pearce RE, Crespi C, et al. (2002). Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metab Dispos 30:595–601
   PubMed Web of Science ®Google Scholar
• Muth EA, Moyer JA, Haskins JT, et al. (1991). Biochemical, neurophysiological, and behavioral effects of Wy45:030. An ethyl cyclohexanol derivative. Drug Dev Res 23:191–3
   Web of Science ®Google Scholar
• Nakamura K, Ariyoshi N, Yokoi T, et al. (2002). CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability. Biochem Biophys Res Commun 293:969–73
   PubMed Web of Science ®Google Scholar
• Nichols AI, Lobello K, Guico-Pabia CJ, et al. (2009). Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status. J Clin Psychopharmacol 29:383–6
   PubMed Web of Science ®Google Scholar
• Oscarson M. (2003). Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine. Clin Chem Lab Med 41:573–80
   PubMed Web of Science ®Google Scholar
• Oscarson M, Hidestrand M, Johansson I, et al. (1997). A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 52:1034–40
   PubMed Web of Science ®Google Scholar
• Otton SV, Ball SE, Cheung SW, et al. (1996). Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 41:149–56
   PubMed Web of Science ®Google Scholar
• Qian JC, Xu XM, Hu GX, et al. (2013). Genetic variations of human CYP2D6 in the Chinese Han population. Pharmacogenomics 14:1731–43
   PubMed Web of Science ®Google Scholar
• Ramamoorthy Y, Tyndale RF, Sellers EM. (2001). Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 11:477–87
   PubMedGoogle Scholar
• Sakuyama K, Sasaki T, Ujiie S, et al. (2008). Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab Dispos 36:2460–7
   PubMed Web of Science ®Google Scholar
• Shen H, He MM, Liu H, et al. (2007). Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos 35:1292–300
   PubMed Web of Science ®Google Scholar
• Yu A, Kneller BM, Rettie AE, et al. (2002). Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J Pharmacol Exp Ther 303:1291–300
   PubMed Web of Science ®Google Scholar
• Zanger UM, Raimundo S, Eichelbaum M. (2004). Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23–7
   PubMed Web of Science ®Google Scholar
• Zhou SF. (2009). Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 48:689–723
   PubMed Web of Science ®Google Scholar
• Zhou SF, Liu JP, Chowbay B. (2009). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89–295
   PubMed Web of Science ®Google Scholar